IL162377A0 - 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists - Google Patents

5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists

Info

Publication number: IL162377A0
Authority: IL; Israel
Prior art keywords: diaryl; pyrazine; antagonists; amide derivatives; amide
Prior art date: 2001-12-19

Application number

IL16237702A

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-19

Filing date

2002-12-18

Publication date

2005-11-20

2002-12-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-11-20 Publication of IL162377A0 publication Critical patent/IL162377A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hematology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL16237702A 2001-12-19 2002-12-18 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists IL162377A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0104330A SE0104330D0 (sv)	2001-12-19	2001-12-19	Therapeutic agents
PCT/GB2002/005742 WO2003051851A1 (fr)	2001-12-19	2002-12-18	Derives de 5, 6-diaryl-pyrazine-2-amide comme antagonistes de cb1

Publications (1)

Publication Number	Publication Date
IL162377A0 true IL162377A0 (en)	2005-11-20

Family

ID=20286429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16237702A IL162377A0 (en)	2001-12-19	2002-12-18	5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists

Country Status (25)

Country	Link
US (1)	US7342019B2 (fr)
EP (1)	EP1458690B1 (fr)
JP (1)	JP2005517655A (fr)
KR (1)	KR20040068286A (fr)
CN (1)	CN1620438A (fr)
AR (1)	AR038044A1 (fr)
AT (1)	ATE354570T1 (fr)
AU (1)	AU2002352425A1 (fr)
BR (1)	BR0214989A (fr)
CA (1)	CA2469786A1 (fr)
CO (1)	CO5590917A2 (fr)
DE (1)	DE60218340T2 (fr)
ES (1)	ES2280599T3 (fr)
HU (1)	HUP0402026A3 (fr)
IL (1)	IL162377A0 (fr)
IS (1)	IS7314A (fr)
MX (1)	MXPA04005990A (fr)
NO (1)	NO20043022L (fr)
NZ (1)	NZ533275A (fr)
PL (1)	PL369731A1 (fr)
RU (1)	RU2004116916A (fr)
SE (1)	SE0104330D0 (fr)
TW (1)	TW200410694A (fr)
WO (1)	WO2003051851A1 (fr)
ZA (1)	ZA200404805B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7704995B2 (en)	2002-05-03	2010-04-27	Exelixis, Inc.	Protein kinase modulators and methods of use
GB0216700D0 (en)	2002-07-18	2002-08-28	Astrazeneca Ab	Process
JP2006510597A (ja)	2002-09-27	2006-03-30	メルク　エンド　カムパニー　インコーポレーテッド	置換ピリミジン類
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
GB0302673D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302671D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US20060135523A1 (en) *	2003-06-18	2006-06-22	Astrazeneca Ab	2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314057D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314049D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314261D0 (en) *	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
US20050014786A1 (en)	2003-07-11	2005-01-20	Chongqing Sun	Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) *	2003-08-15	2008-02-05	Bristol-Myers Squibb Company	Pyrazine modulators of cannabinoid receptors
EP1663215A1 (fr) *	2003-09-02	2006-06-07	Solvay Pharmaceuticals GmbH	Nouvelle utilisation medicale d'antagonistes selectifs du receptor cb1
US7320805B2 (en) *	2003-10-01	2008-01-22	Institut National De La Sante Et De La Recherche Medicale	CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
WO2005037199A2 (fr)	2003-10-10	2005-04-28	Bristol-Myers Squibb Company	Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide
TW200528102A (en) *	2003-10-24	2005-09-01	Solvay Pharm Gmbh	Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005039579A1 (fr) *	2003-10-24	2005-05-06	Solvay Pharmaceuticals Gmbh	Traitement de l'obesite combinant des antagonistes de cb1 selectifs et des inhibiteurs de lipase
GB0327331D0 (en) *	2003-11-25	2003-12-31	Astrazeneca Ab	Therapeutic agents
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
TW200602314A (en)	2004-05-28	2006-01-16	Tanabe Seiyaku Co	A novel pyrrolidine compound and a process for preparing the same
CA2585175A1 (fr)	2004-10-25	2006-05-04	Solvay Pharmaceuticals Gmbh	Compositions pharmaceutiques contenant des antagonistes des recepteurs cannabinoides et des agents d'ouverture de canaux potassiques dans le traitement du diabete insulino-dependant, de l'obesite et des etats associes
MX2007012213A (es)	2005-04-06	2007-12-10	Hoffmann La Roche	Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
JP2008536950A (ja) *	2005-04-18	2008-09-11	ニューロジェン・コーポレーション	置換ヘテロアリールのｃｂ１拮抗薬
KR20080027908A (ko)	2005-06-30	2008-03-28	프로시디온 리미티드	Ｇｐｃｒ 효능제
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en)	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
MX2009003222A (es) *	2006-10-04	2009-04-06	Hoffmann La Roche	Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.
SI2114933T1 (sl)	2007-01-04	2012-01-31	Prosidion Ltd Windrush Court	Piperidinski gpcr-agonisti
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
AR064736A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
JP2010514832A (ja)	2007-01-04	2010-05-06	プロシディオン・リミテッド	ピペリジンｇｐｃｒアゴニスト
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
WO2010079241A1 (fr)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
US12036292B2 (en)	2020-08-06	2024-07-16	Chdi Foundation, Inc.	Heterobiaryl compounds and imaging agents for imaging huntingtin protein
AR131690A1 (es) *	2023-01-30	2025-04-23	Eurofarma Laboratorios S A	COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
AR131658A1 (es) *	2023-01-30	2025-04-16	Eurofarma Laboratorios S A	Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH458361A (de) *	1965-01-15	1968-06-30	Eprova Ag	Verfahren zur Herstellung von Pyrazincarbonsäuren
JPS5322529A (en) *	1976-08-13	1978-03-02	Nippon Soda Co Ltd	Dihydropyrazine derivative and its preparation
EP0397859A4 (en) *	1987-11-12	1990-12-19	Terumo Kabushiki Kaisha	Pyrazine derivatives and medicinal preparation containing same
WO1992002513A1 (fr)	1990-08-06	1992-02-20	Fujisawa Pharmaceutical Co., Ltd.	Composes heterocycliques
FR2713225B1 (fr)	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.

2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
2002
- 2002-12-18 CA CA002469786A patent/CA2469786A1/fr not_active Abandoned
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 EP EP02788143A patent/EP1458690B1/fr not_active Expired - Lifetime
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/fr not_active Ceased
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Withdrawn
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1620438A (zh)	2005-05-25
PL369731A1 (en)	2005-05-02
JP2005517655A (ja)	2005-06-16
AR038044A1 (es)	2004-12-22
NO20043022L (no)	2004-07-15
MXPA04005990A (es)	2004-09-27
HUP0402026A2 (hu)	2005-02-28
DE60218340D1 (de)	2007-04-05
WO2003051851A1 (fr)	2003-06-26
CO5590917A2 (es)	2005-12-30
BR0214989A (pt)	2004-12-14
KR20040068286A (ko)	2004-07-30
RU2004116916A (ru)	2005-11-10
TW200410694A (en)	2004-07-01
EP1458690A1 (fr)	2004-09-22
CA2469786A1 (fr)	2003-06-26
ES2280599T3 (es)	2007-09-16
HUP0402026A3 (en)	2005-08-29
EP1458690B1 (fr)	2007-02-21
NZ533275A (en)	2006-02-24
SE0104330D0 (sv)	2001-12-19
IS7314A (is)	2004-06-16
DE60218340T2 (de)	2007-11-29
US20050032808A1 (en)	2005-02-10
US7342019B2 (en)	2008-03-11
ATE354570T1 (de)	2007-03-15
ZA200404805B (en)	2005-08-15
AU2002352425A1 (en)	2003-06-30

Publication	Publication Date	Title
IL162377A0 (en)	2005-11-20	5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
IL157704A0 (en)	2004-03-28	4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity
DK1429761T3 (da)	2007-02-05	Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
NO20032892L (no)	2003-11-18	4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
SI1555267T1 (sl)	2013-05-31	2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
SI1699795T1 (sl)	2007-10-31	Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
IL160708A0 (en)	2004-08-31	1, 6-naphthyridine derivatives as antidiabetics
ZA200309522B (en)	2005-02-23	Substituted cyclohexane-1-4diamine derivatives
IL150550A0 (en)	2003-02-12	1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
MXPA03006991A (es)	2003-11-18	Derivados de piperidina como antagonistas de neurocinina 1.
MXPA03008140A (es)	2003-12-12	Amidas de acido benzofuran-2-carboxilico sustituidas.
EG23207A (en)	2004-07-31	Novel fungicidal compositions based on propamocarsand pyridylmethylbenzamide derivatives.
IL162310A0 (en)	2005-11-20	3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
GB0130553D0 (en)	2002-02-06	1,4-Dihydro-1,4-diphenylpyridine derivitives
MXPA03008394A (es)	2004-01-29	Derivados de biuretano.
IL159965A0 (en)	2004-06-20	Novel 2,4-diaminothiazole derivatives
HK1068617A (en)	2005-04-29	5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
AU2003223100A8 (en)	2003-09-04	1,2,4-triazol-1-yl-propan-2-ol derivatives as anti-fungal agents
SI1497256T1 (sl)	2010-10-29	Substituirane 1,5-diaminopentan-3-olne spojine
AU2003255737A8 (en)	2004-02-16	Antimicrobial 2, 4-diamino-pteridine derivatives
PL371851A1 (en)	2005-06-27	3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
AU2002341261A1 (en)	2003-05-26	N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
EG23305A (en)	2004-11-30	Preparation of 1,2-dicloroethane.
SI1549647T1 (sl)	2006-10-31	Substituirani C-imidazo(1,2-a)piridin-3-il-metilamini
AU2002345403A1 (en)	2003-03-03	Novel 2,4-difluorobenzamide derivatives as antiviral agents